INTRODUCTION
Ligand-mediated targeting of liposomal anticancer drugs to antigens that are either expressed selectively, or are overexpressed, on the surface of tumor cells is increasingly being recognized as an effective strategy for increasing the therapeutic effectiveness of anticancer drugs (1-7). However, low antigen density and/or heterogeneous expression of the target antigen at the cell surface may limit the effectiveness of targeted therapeutics (7) (8) (9) (10) .
Evidence has been presented that high antigen density on target cells improves the therapeutic effectiveness of targeted, relative to nontargeted, liposomal drugs by increasing the amount of drug delivered to the target cells (5) . In addition, for antibody-targeted liposomal (immunoliposomal) drugs, antibodies are presented in a multivalent fashion at the liposome surface, and high antigen densities may facilitate the simultaneous engagement of multiple antigenic sites, which can initiate signal transduction mechanisms and lead to increased cell killing. Because increasing the density of a single population of receptors at the cell surface is impractical for in vivo applications, a possible approach to increasing the total targeted population of receptors at the cell surface would be to use a mixture of immunoliposomal drugs, with the immunoliposomes in the mixture being targeted against different populations of receptors. We hypothesize that combinations of immunoliposomal drugs, targeted against different populations of cell surface antigens, will lead to a higher apparent antigen density on the target cells, the delivery of more drug to the cells, and greater cell killing.
Antibody-based therapies, including immunoliposomes, target and kill individual cells that express specific cell-surface antigens; tumor cells that have little or no target antigen may be killed by a bystander effect or may escape cytotoxic effects (7) . The antigen-negative cells can result in emergence of resistant cell populations and disease relapse (11) . Using mixtures of immunoliposomes should facilitate delivery of drugs to a higher percentage of tumor cells in populations of cells that have heterogeneous expression of receptors. Several studies have shown significantly improved therapeutic responses when using combinations of immunotoxins compared with single immunotoxin therapy in animal cancer models (12) (13) (14) (15) (16) (17) .
Immunoliposomal therapy has, to date, only targeted individual antigens on tumor cells surfaces; combination immunoliposomal therapy has yet to evaluated. In this study, we examined the therapeutic efficacy, in xenograft models of human B lymphoma, of combination regimens of immunoliposomes, loaded with either doxorubicin (DXR) or vincristine (VCR), targeted to two different epitopes, CD19 (internalizing) and CD20 (noninternalizing or very slow internalizing; Refs. 1, 18, 19) . We show that this strategy resulted in an improved therapeutic outcome for VCR-loaded liposomes relative to DXRloaded liposomes.
Internalization of the liposome-drug package is generally accepted to be a requirement for successful immunoliposomal drug therapy (1, 20, 21) . It has been shown recently that DXRloaded immunoliposomes required internalization into Namalwa cells to improve the therapeutic responses over those obtained with nontargeted liposomes (1). Here we report, in the same animal model, the unexpected finding that mice injected with VCR-loaded immunoliposomes targeted via anti-CD20 (Rituxan; mouse:human chimeric IgG 1 anti-CD20 antibody; ␣CD20), had significantly increased survival rates relative to nontargeted liposomes. Indeed, survival rates for ␣CD20-targeted immunoliposomal VCR were comparable with those found in mice injected with anti-CD19 (anti-CD19 murine monoclonal antibody IgG 2a ; ␣CD19)-targeted immunoliposomal VCR.
purified as described previously (25) . Rituxan, a chimeric whole mAb (IgG1) used as a source of ␣CD20, was purchased from the University of Alberta Hospital Pharmacy. The human Burkitt's lymphoma cell line, Namalwa (American Type Culture Collection CRL 1432), was purchased from American Type Culture Collection (Rockville, MD) and cultured in suspension in a humidified 37°C incubator with a 5% CO 2 atmosphere in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum, penicillin G (50 units/ml), and streptomycin sulfate (50 g/ml). Only cells in the exponential phase of cell growth were used for experiments.
Preparation of Liposomes. Nontargeted Stealth liposomes (SL), to be loaded with DXR for therapeutic studies or radiolabeled with [ 3 H]CHE for cell association studies, were composed of HSPC:Chol:mPEG-DSPE at a 2:1:0.1 molar ratio (HSPC-SL) and targeted Stealth immunoliposomes (SIL) were composed of HSPC:Chol:mPEG-DSPE:Mal-PEG-DSPE at a 2:1:0.08:0.02 molar ratio (HSPC-SIL). Liposomes were prepared by hydration of thin films, as described previously, and were extruded to mean diameters in the range of 100 Ϯ 10 nm (2). DXR was loaded into liposomes using the ammonium sulfate loading method (26) .
Nontargeted liposomes, to be loaded with VCR for therapeutic studies or radiolabeled with [ 3 H]CHE for cell association studies, were composed of SM:Chol:mPEG-DSPE at a 55:40:5 molar ratio (SM-SL), and targeted liposomes were composed of SM:Chol:mPEG-DSPE:Mal-PEG-DSPE at a 55:40:4:1 molar ratio (SM-SIL). Liposomes were prepared by hydration of a lipid film in 300 mM citrate buffer (pH 4.0) as described previously (27) and were extruded to a mean diameter of 120 Ϯ 10 nm. VCR was loaded using the transmembrane pH gradientdependent procedure (28) .
Liposomes for the in vitro cell association studies were radiolabeled with [ 3 H]CHE], a nonmetabolizable, nonexchangeable radioactive tracer, and were prepared by hydrating the lipid films in HEPES-buffered saline [25 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid and 140 mM NaCl (pH 7.4)] followed by extrusion, as above.
Coupling of mAbs to Liposomes. ␣CD19 or ␣CD20 mAbs were coupled to the terminus of the Mal-PEG-DSPE included in HSPC-SIL or SM-SIL at 2000:1 (lipid:protein) molar ratios, using a coupling procedure described previously (23) . Briefly, mAb (10 mg/ml) was incubated with 2-iminothiolane in O 2 -free HEPES-buffered saline (pH 8.0) at a ratio of 20:1 (mol/mol) for 1 h at room temperature to thiolate the amino groups. At the end of the incubation, the excess reagent was removed by chromatography on a Sephadex G-50 column, equilibrated with O 2 -free HEPES-buffered saline (pH 7.4), and the thiolated mAb was immediately incubated overnight with liposomes in an O 2 -free environment with continuous stirring. The SIL were separated from any uncoupled mAb over a Sephadex CL-4B column equilibrated with HEPES-buffered saline (pH 7.4). To assess coupling efficiency of the mAbs, a trace amount of 125 I-labeled ␣CD19 or ␣CD20 was added to the unlabeled mAb before thiolation. Antibody coupling is expressed as g mAb/mol phospholipid (PL). A coupling efficiency of 80 -90% for either antibody could routinely be achieved by this procedure, and particular attention was taken to ensure that similar antibody densities (within Ϯ10%) occurred at the surface of either type of immunoliposome.
Cell Association of Immunoliposomes. In vitro cell association of immunoliposomes labeled with [ 3 H]CHE was determined, as described previously, at both 37°C and 4°C, i.e., permissive and nonpermissive temperatures for endocytosis, respectively (29) . Briefly, liposomes {SM-SL, HSPC-SL, SIL composed of SM:Chol:mPEG-DSPE:Mal-PEG-DSPE conjugated to ␣CD19 [SM-SIL(␣CD19)], SIL composed of HSPC: Chol:mPEG-DSPE:Mal-PEG-DSPE conjugated to ␣CD19 [HSPC-SIL(␣CD19)], SIL composed of SM:Chol:mPEG-DSPE: Mal-PEG-DSPE conjugated to ␣CD20 [SM-SIL(␣CD20)], or SIL composed of HSPC:Chol:mPEG-DSPE:Mal-PEG-DSPE conjugated to ␣CD20 [HSPC-SIL(␣CD20)]} were radiolabeled with [
3 H]CHE and incubated in sterile tubes with 1 million Namalwa cells at PL concentrations ranging from 0.1 mM to 1.6 mM PL (in triplicate) for 1 h. For evaluating cell association of combinations of immunoliposomes, HSPC-SIL(␣CD19) and HSPC-SIL(␣CD20) or SM-SIL(␣CD19) and SM-SIL(␣CD20) were mixed at a 1:1 ratio before incubation with the Namalwa cells. Cells were then washed twice with cold PBS to remove unbound liposomes, and the amount of [ 3 H]CHE counts associated with cells was determined by scintillation counting (Beckman LS-6800 Scintillation Counter). These data were transformed into pmol PL uptake per 10 6 cells (cell association) using the specific activity of the liposomes. Specific cell association of either SIL[␣CD19] or SIL[␣CD20] was determined by subtracting cell association for nontargeted liposomes (nonspecific association) from the total cell association of the respective immunoliposome.
In Vivo Survival Experiments. Severe compromised immunodeficient mice (5-7/group) were injected i.v. via the tail vein with 5 million Namalwa cells in 0.2 ml PBS. After 24 h, mice received a single bolus i.v. dose of 3 mg DXR/kg as free DXR or DXR-loaded liposomes [DXR-HSPC-SL, DXR-HSPC-SIL(␣CD19), or DXR-HSPC-SIL(␣CD20)]. Alternatively, mice were injected with 0.66 mg VCR/kg as free VCR or VCRloaded liposomes [VCR-SM-SL, VCR-SM-SIL(␣CD19), or VCR-SM-SIL(␣CD20)]. The antibody density on drug-loaded immunoliposomes was used to calculate appropriate doses of either free mAb or empty (no drug) immunoliposomes that were used as experimental controls. Where combinations of two drug-loaded immunoliposomal formulations, two free mAbs, or two empty immunoliposomal formulations were administered, the total dose was composed of equal parts of each therapy. Mice were monitored daily for up to 150 days and were euthanized when they developed hind leg paralysis. Mice surviving to 150 days were determined to be long-term survivors and were subsequently sacrificed and subjected to gross pathological examination.
Statistical Analysis. Comparisons of cell association and survival studies reported in Table 1 were done using one-way ANOVA with InStat software (Version 3.0; GraphPad, San Diego, CA). The Tukey post-test was used to compare means. Survival studies reported in Table 2 were analyzed using Kaplan-Meier plots with GraphPad Prism software. Differences were considered significant at a P Ͻ 0.05.
RESULTS AND DISCUSSION

In Vitro Cell Association
In vitro cell association studies were performed on Namalwa cells with either SIL(␣CD19) or SIL(␣CD20). The term cell association reflects a combination of three processes: (a) specific bind- or 70 g ␣CD20/mol PL (37 molecules of ␣CD20/liposome), respectively. Free mAbs were dosed at 15 g of ␣CD19 or 13 g of ␣CD20 per mouse, which corresponds to the total amount of mAb received on immunoliposomes. Empty liposomes had 36 molecules of ␣CD19/liposome or 33 molecules of ␣CD20/liposome. The combination groups of free mAbs, empty or DXR-loaded liposomes had both components in equal parts. The combination of DXR-loaded ␣CD19 and ␣CD20-targeted liposomes was dosed at a total DXR dose of 3 mg/kg, and a total dose of 14 g free mAbs per mouse. The levels of cell association of either SIL(␣CD19) or SIL(␣CD20) with Namalwa cells were significantly higher than seen for nontargeted SLs at either 37°C or 4°C (Fig. 1A) at all of the phospholipid concentrations. In addition, the levels of cell association of SIL(␣CD19) with cells were significantly higher at 37°C than at 4°C (nonpermissive for endocytosis; Fig. 1A ). This was likely due to the binding of SIL to Namalwa cells via the pan B-cell differentiation antigen, CD19, followed by receptor-mediated endocytosis and recycling of the epitope back to the cell surface where it is available to participate in additional binding and internalization events (2, 18, 30, 31) . No significant differences were observed in the levels of cell association of SIL(␣CD20) with cells at 37°C versus 4°C, which is consistent with its poor ability to internalize immunoliposomes (1). Also, using confocal fluorescence microscopy, we have shown previously that SIL(␣CD19) were rapidly internalized into Namalwa cells at 37°C whereas SIL(␣CD20) were not internalized at this temperature. At 4°C, both SIL(␣CD19) and SIL(␣CD20) were largely found on the cell surface consistent with the poor ability of CD20 epitope to internalize (1, 18, 19) . Specific cell association (targeted minus nontargeted) is given in Fig. 1B . As expected, the levels of cell association of 1:1 combinations of SIL(␣CD19) and SIL(␣CD20) were higher than those seen for either of the individual immunoliposome formulations at all of the PL concentrations and appeared to be additive. This was observed for both SM and HSPC liposomes at either 37°C or 4°C (Fig. 2) . Only at one concentration (1.6 mM PL), at 37°C, did the cell association of the combination of HSPC-SIL(␣CD19) and HSPC-SIL(␣CD20) appear to be subadditive.
Group
In Vivo Survival Studies
DXR-Containing Liposomes. The therapeutic effectiveness of DXR-loaded immunoliposomes targeted via either ␣CD19 or ␣CD20 was evaluated individually or in combination in severe compromised immunodeficient mice bearing Namalwa cells (Table 1) . Mice treated with DXR-containing liposomes targeted via either ␣CD19 or ␣CD20 had significantly longer survival times than mice that received no treatment (control; P Ͻ 0.01). DXR-HSPC-SL or free DXR were not therapeutically better than control groups (P Ͼ 0.05). These results confirm previous observations that antibody-mediated delivery of liposomal drugs to antigens expressed on the surface of B cells can increase the therapeutic effectiveness of anticancer drugs.
A single injection of free DXR was not an effective treatment, in part because the drug has large volume of distribution, leading to low plasma drug levels. The release rate of DXR from liposomes is slow, so nontargeted liposomal DXR maintains high levels of entrapped (i.e., nonbioavailable) drug in circulation for long periods of time (32) . However, the entrapped drug is not delivered efficiently to B cells, because nontargeted liposomes are not bound to and internalized by these cells. This makes it unlikely that therapeutically relevant intracellular concentrations of drug are achieved for the nontargeted liposomes, explaining their lack of significant therapeutic effects.
As seen in Table 1 , treatment of tumor-bearing mice with DXR-HSPC-SIL(␣CD19) significantly increased their survival relative to DXR-HSPC-SIL(␣CD20; P Ͻ 0.001), DXR-HSPC-SL (P Ͻ 0.001), or free DXR (P Ͻ 0.001). No significant difference was observed between mice treated with DXR-HSPC-SIL(␣CD20) and free DXR (P Ͼ 0.05). Mice treated with DXR-HSPC-SIL(␣CD20) had survival times that were marginally better than DXR-HSPC-SL (P Ͻ 0.05).
As reported previously, immunoliposomes targeted via ␣CD19 are rapidly internalized into Namalwa cells in contrast to immunoliposomes targeted via ␣CD20, which are not internalized or are internalized very slowly (1) . Internalization of the ␣CD19-targeted formulations is the likely explanation of the improved results seen for DXR-HSPC-SIL(␣CD19) relative to DXR-HSPC-SIL(␣CD20). Receptor-mediated intracellular delivery of DXR-HSPC-SIL(␣CD19) and subsequent release of drugs inside the cells leads to high intracellular drug concentra- tions. We have published previously evidence that breakdown of the drug-liposome package by lysosomal and endosomal enzymes, followed by release of drug into the cytoplasm, is responsible for cytotoxic effects of DXR-HSPC-SIL(␣CD19; Refs. [33] [34] [35] . In contrast, DXR-HSPC-SIL(␣CD20) will bind to the surface of target cells and, over time, release drug to the extracellular medium. The processes of diffusion and redistribution of the drug away from the cell surface in vivo competes with entry of the drug into the cell by passive diffusion and leads, we hypothesize, to low intracellular drug concentrations and inferior therapeutic results.
Another explanation for improved results seen with DXR-HSPC-SIL(␣CD19) over DXR-HSPC-SIL(␣CD20) may lie in the more homogeneous distribution of the CD19 epitope in Namalwa cell populations compared with the CD20 epitope (coefficient of variation for CD20 ϭ 78, CD19 ϭ 45, unstained cells ϭ 44; Ref. 1). A more homogeneous expression of the CD19 epitope on the target cells would lead to a higher overall level of cell killing for the DXR-HSPC-SIL(␣CD19) relative to DXR-HSPC-SIL(␣CD20), which would not be expected to be effective against cells that had low or no expression of CD20.
In this study, the combination of DXR-HSPC-SIL(␣CD19) and DXR-HSPC-SIL(␣CD20) did not significantly improve the therapeutic effectiveness over that seen with DXR-HSPC-SIL(␣CD19) alone (P Ͼ 0.05; Table 1 ). Not surprisingly, because DXR-HSPC-SIL(␣CD20) alone had little or no therapeutic effect, this combination was more effective than DXR-HSPC-SIL(␣CD20) alone (P Ͻ 0.0005). Mice injected with a combination of DXR-HSPC-SIL(␣CD19) and DXR-HSPC-SIL(␣CD19) had significantly improved survival time over mice injected with a combination of free mAbs (P Ͻ 0.005) or a combination of drug-free immunoliposomes (P Ͻ 0.0005).
Mice injected with either free ␣CD19 or ␣CD20 had significantly longer survival times than untreated controls (P Ͻ 0.01; Table 1 ). It was interesting to observe that free ␣CD19 and free ␣CD20 given in combination were significantly better than individual mAbs (P Ͻ 0.0001); this could be due to the higher total binding of the two populations of mAbs on the cell surface, i.e., higher apparent antigen density, possibly leading to increases in signal transduction mechanisms.
Unlike treatments with comparable amounts of free ␣CD19 or ␣CD20, injection of mice with drug-free liposomes, conjugated to either ␣CD19 or ␣CD20, did not improve the survival times of mice compared with untreated controls (Table 1) . Drug-free immunoliposomes, despite the multivalent display of mAbs at the liposome surface, may be less effective than similar concentration of free mAbs, because the orientation of the bound antibodies with respect to the liposome surface might shield the Fc segment and hinder cell killing via mechanisms involving complement-dependent cytotoxicity and/or antibodydependent cell-mediated cytotoxicity. Alternatively, different cellular processing pathways for the free mAbs versus the immunoliposomes may account for the different effects of each.
Free ␣CD19, but not free ␣CD20, improved the anticancer effect of nontargeted liposomal DXR ( Table 1) . The DXR-HSPC-SL ϩ free ␣CD19 combination was therapeutically more effective than control treatments, free DXR, free ␣CD19, or DXR-HSPC-SL (P Ͻ 0.001). However, targeting the liposomes via ␣CD19 [DXR-HSPC-SIL(␣CD19)] was significantly more effective than giving nontargeted liposomes plus free antibody (P Ͻ 0.01). The combination of DXR-HSPC-SL and free ␣CD20 was not therapeutically better than control treatments, free DXR, or DXR-HSPC-SL (P Ͼ 0.05). DXR-HSPC-SIL(␣CD20) was also not better than the combination of DXR-HSPC-SL and free ␣CD20 (P Ͻ 0.05).
VCR-Containing Liposomes. We performed a separate study to evaluate the therapeutic effects of VCR-containing liposomes conjugated to either ␣CD19 or ␣CD20, used individually or in combination (Table 2 ). An unexpected observation was that treatment with VCR-SM-SIL(␣CD20) increased the survival of mice to a significantly greater extent than either VCR-SM-SL or free VCR (P Ͻ 0.005) and was not significantly different from VCR-SM-SIL(␣CD19; P Ͼ 0.05). In this study, there was a tendency for a higher cure rate in mice treated with a combination of VCR-SM-SIL(␣CD19) and VCR-SM-SIL(␣CD20), relative to either treatment alone, although this did not reach statistical significance (P Ͼ 0.05). Five of 7 mice injected with the combination were long-term survivors (Ͼ150 days), with no evidence of tumor on gross pathological examination, and the remaining 2 mice had significantly improved life spans. The high cure rate was probably due to an additive effect of the individual therapies (Table 2 ).
An explanation for the improved therapeutics of VCR-SM-SIL(␣CD20), relative to DXR-HSPC-SIL(␣CD20), may lie in the faster rate of release from liposomes of VCR relative to DXR (32) . Because free VCR has better therapeutic activity than free DXR in this therapeutic model (P Ͻ 0.005; Table 1  versus Table 2 ), the faster release of VCR from VCR-SM-SIL(␣CD20) may lead to higher extracellular concentrations of drug at the cell surface and higher cytotoxic levels of drug being delivered internally to the cells, relative to DXR-HSPC-SIL(␣CD20).
As observed for DXR-containing liposomes, VCR-containing liposomes had increased cytotoxic effects when combined with either free ␣CD19 or ␣CD20 mAbs (Table 2) . Therapy with the combination of nontargeted liposomal VCR and either free ␣CD20 or free ␣CD19 was significantly better than controls (P Ͻ 0.005), therapy with free VCR (P Ͻ 0.05), or with VCR-SM-SL (P Ͻ 0.005). Targeting the immunoliposomal VCR via either ␣CD20 or ␣CD19 [i.e., VCR-SM-SIL(␣CD19) or VCR-SM-SIL(␣CD20)] was significantly better than the combination of nontargeted liposomal VCR and free antibodies (P Ͻ 0.01).
Previous studies have reported that Vinca alkaloid-containing immunoconjugates do not require internalization for therapeutic activity (36, 37) . The authors proposed that cytotoxicity of these immunoconjugates might be due to the release of free drug from the conjugate at tumor cell periphery, followed by intracellular transport. On the other hand, studies have shown that Adriamycin conjugates linked to internalizing antibodies have significantly improved therapeutics over Adriamycin conjugates linked to noninternalizing antibodies (␣CD20; 38), which is in accordance with our previous observations for DXR-containing immunoliposomes (1) . In another study, antibody-drug conjugates composed of ␣CD20 (Rituxan) and the drug monomethyl auristatin demonstrated significantly improved therapeutic outcomes over conjugates made from DXR and Rituxan (39) . Monomethyl auristatin is a derivative of
